Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasms

Kais Hussein, Bianca M. Engelhardt, Hans Kreipe, Oliver Bock

Blood (2010) 116 (23): 5073–5074.

https://doi.org/10.1182/blood-2010-06-290791

Published: 2010

Journal Articles

JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Nicolaus Kröger, Haefaa Alchalby, Evgeny Klyuchnikov, Anita Badbaran, York Hildebrandt, Francis Ayuk, Ulrike Bacher, Oliver Bock, Michael Kvasnicka, Boris Fehse, Axel Zander

Blood (2009) 113 (8): 1866–1868.

https://doi.org/10.1182/blood-2008-11-190975

Published: 2009

Journal Articles

Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPL W515L /JAK2 V617F mutation

Kais Hussein, Oliver Bock, Katharina Theophile, Jerome Schlue, Matthias Ballmaier, Nicolaus Kröger, Gudrun Göhring, Guntram Büsche, Hans Kreipe

Blood (2009) 113 (6): 1391–1392.

https://doi.org/10.1182/blood-2008-01-136499

Published: 2009

Includes: Supplemental data

Journal Articles

Coincidence of bcr/abl-Positive Chronic Myeloid Leukemia and bcr/abl-Negative Chronic Myeloproliferative Disorder and Its Relevance to the Course of Disease.

Guntram Buesche, Oliver Bock, Kais Hussein, Nils von Neuhoff, Brigitte Schlegelberger, Hans H. Kreipe

Blood (2007) 110 (11): 2950.

https://doi.org/10.1182/blood.V110.11.2950.2950

Published: 2007

Journal Articles

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2 V617F mutation

Kais Hussein, Oliver Bock, Anna Seegers, Michael Flasshove, Felicitas Henneke, Guntram Buesche, Hans Heinrich Kreipe

Blood (2007) 109 (9): 4106–4107.

https://doi.org/10.1182/blood-2006-12-061135

Published: 2007

Journal Articles

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

Guntram Buesche, Stephanie Dieck, Aristoteles Giagounidis, Oliver Bock, Ludwig Wilkens, PD, Brigitte Schlegelberger, Robert Knight, John Bennett, Carlo Aul, Hans H. Kreipe

Blood (2005) 106 (11): 372.

https://doi.org/10.1182/blood.V106.11.372.372

Published: 2005

Journal Articles

Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression

Oliver Bock, Jerome Schlué, Ulrich Lehmann, Reinhard von Wasielewski, Florian Länger, Hans Kreipe

Blood (2002) 100 (6): 2274–2275.

https://doi.org/10.1182/blood-2002-06-1811

Published: 2002

NARROW

IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasms

JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPL W515L /JAK2 V617F mutation

Coincidence of bcr/abl-Positive Chronic Myeloid Leukemia and bcr/abl-Negative Chronic Myeloproliferative Disorder and Its Relevance to the Course of Disease.

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2 V617F mutation

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression

Email alerts

ASH Publications

American Society of Hematology

IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasms

JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPL W515L /JAK2 V617F mutation

Coincidence of bcr/abl-Positive Chronic Myeloid Leukemia and bcr/abl-Negative Chronic Myeloproliferative Disorder and Its Relevance to the Course of Disease.

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2 V617F mutation

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only